Search News + Media

Rutgers Cancer Institute of New Jersey and Tufts Medical Center Collaboration Published in Journal of Clinical Oncology.

National Cancer Institute Grant Awarded to Tufts Medical Center and Rutgers Cancer Institute of New Jersey Collaborators.

Tufts Medical Center announced today that it has become the first center in New England to use the drug Jelmyto (UroGen Pharma, Inc.) for treatment of upper tract urothelial cancer (UTUC), a malignancy found in the kidney lining or the ureter, the thin tube connecting the bladder to the kidneys.

Tufts Medical Center announced today that Rachel J. Buchsbaum, MD, has been named Director of the Cancer Center, effective August 12, 2019. Dr. Buchsbaum, a nationally-recognized physician, researcher, educator and leader in breast cancer therapy, risk assessment and prevention, will steer the cancer programs at Tufts MC.